All articles tagged with #fatty liver disease
A large observational study finds that eating late at night is associated with a 35% higher risk of fatty liver disease and a 28% higher risk of cirrhosis. Researchers suggest that misaligning meal times with the body's circadian rhythm disrupts liver metabolism, leading to fat accumulation. The findings emphasize that meal timing, not just food content, impacts long-term liver health.
A large UK Biobank study confirms that 3-4 cups of coffee daily significantly reduce risks of cirrhosis, liver cancer, and liver-related death. However, adding sugar or artificial sweeteners negates these benefits, potentially increasing fibrosis risk. Experts advise plain coffee as a protective measure, not a cure, for metabolic liver disease.
A new randomized trial confirms that while all diets yield similar weight loss, ketogenic diets offer superior benefits for liver fat reduction and blood sugar control compared to Mediterranean or high-carb diets.
A new study from UC San Diego defines 'early-onset cirrhosis' caused by fatty liver disease, finding that 25% of cases occur before age 50. These patients have a unique risk profile involving genetic factors and type 2 diabetes, which current age-based screening tools often miss.
About 1 in 4 U.S. adults have metabolic dysfunction-associated steatotic liver disease (MASLD), a largely undiagnosed but potentially reversible condition. The piece highlights three foods to minimize: sugar-sweetened drinks, fried foods, and refined carbohydrates, explaining how sugar drives fat buildup in the liver and how fat, refined carbs, and even alcohol contribute to MASLD risk. It also recommends a Mediterranean-style diet, fruit (especially berries), dark chocolate in moderation, and regular coffee as liver-friendly choices to help prevent MASLD.
A preclinical study in obese mice shows the oral compound TOFA reduces body weight by about 18% without changing food intake or causing muscle loss, by both limiting fat production and increasing cellular energy expenditure (about 18%). TOFA also improves fatty liver disease and blood lipid markers. When combined with obesity drugs like semaglutide (Ozempic/Wegovy) or tirzepatide (Mounjaro/Zepbound), the cotreatments outperform single drugs and maintain weight loss longer after treatment ends, suggesting a complementary mechanism that could enhance current therapies. Human safety and dosing remain unknown, and the work is limited to animal models.
Over a billion people have excess liver fat, with fatty liver disease affecting around 30% of adults; AI could mine health records, blood tests, and routine imaging to flag those at highest risk of fibrosis, enabling early lifestyle changes or targeted therapies, and easing primary-care workloads with tools like LiverPRO and ALADDIN—though biopsies and imaging won't disappear, these apps could improve triage and curb costs.
An experimental glycine-based tripeptide called DT-109 reversed severe metabolic dysfunction–associated steatohepatitis (MASH) in animal studies by strengthening the gut barrier and lowering intestinal ammonia, disrupting the harmful gut-to-liver inflammatory loop; findings in mice and nonhuman primates point to a new gut-targeted therapy approach for MASH, with clinical trials needed to assess safety and effectiveness in people.
In a cross-sectional study of 95 young women referred for PMOS (formerly PCOS), 42% had hepatic steatosis and 6% had liver fibrosis. Steatosis was associated with older age, higher BMI, systemic inflammation, higher metabolic syndrome score, and insulin resistance, while hyperandrogenism was more common in those with steatosis. Noninvasive fibrosis scores (FIB-4 and the Steatosis-Associated Fibrosis Estimator) missed the majority of fibrosis cases, suggesting FibroScan evaluation and age-appropriate screening strategies are needed for PMOS patients.
A mouse study presented at ENDO 2026 found that removing sucrose from a low-fat diet did not improve metabolic health but disrupted the gut microbiome, caused intestinal and liver inflammation, and worsened glucose tolerance and insulin resistance, despite similar weight to controls, suggesting that completely eliminating sugar may be counterproductive and that balanced carbohydrate intake supports gut and metabolic health.
A 16-week study in mice found that a sugar-free, low-fat diet caused impaired glucose tolerance and reduced insulin sensitivity, with inflammation in the colon and liver and signs of fatty liver disease, despite similar weight gain to controls. The sugar-free group also showed gut microbiome changes, including lower levels of beneficial Lactobacillus murinus and higher inflammatory bacteria. Findings were presented at ENDO 2026 and have not yet undergone peer review; relevance to humans remains to be determined.
In India, fatty liver disease is rising with obesity and metabolic disorders and often progresses silently. Early detection combined with modest, sustainable weight loss—about 5% to reduce liver fat and 7–10% to reduce inflammation, equating to roughly 4–8 kg for an 80 kg person—can reverse early liver damage and possibly fibrosis. Crash diets can worsen outcomes. If untreated, fatty liver can advance to steatohepatitis, cirrhosis, liver failure, or cancer, sometimes necessitating transplantation. The message is to pursue gradual lifestyle changes— healthier diet, regular exercise, better diabetes control, adequate sleep, and limited alcohol intake.
A UVM PhD candidate physician studies how a Western-style diet with binge drinking accelerates fatty liver disease using a mouse model that mirrors human patterns; findings show rapid progression from fatty liver to inflammatory disease within about 12 weeks, especially in males, with no FDA-approved treatment—emphasizing prevention through food-system changes like greater access to minimally processed foods and reduced high-sugar products, while also exploring sex differences and dietary fat sources. The work underscores a systems-level approach to a medical problem and has earned the Graduate Research Excellence Award.
A decades-old asthma drug, formoterol, reversed fatty liver damage in mice modeling MASH and showed associations with fewer severe liver complications in people taking beta-2 agonists; MUSC researchers are moving to human trials to test whether the drug can treat MASH and diabetic kidney disease by boosting beta-2 signaling and mitochondrial biogenesis, though causal proof in humans is not yet established.
A new study suggests the sugar-free sweetener sorbitol may damage the liver similarly to fructose and contribute to fatty liver disease.